| # | Title | Journal | Year | Citations |
|---|
| 1 | Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study | Lancet, The | 2016 | 389 |
| 2 | Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial | Lancet, The | 2018 | 324 |
| 3 | Postibrutinib outcomes in patients with mantle cell lymphoma | Blood | 2016 | 228 |
| 4 | Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study | Lancet Haematology,the | 2019 | 146 |
| 5 | Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma | Annals of Oncology | 2018 | 106 |
| 6 | Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma | Blood | 2019 | 94 |
| 7 | ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma | Hematological Oncology | 2019 | 82 |
| 8 | 2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland | European Journal of Haematology | 1999 | 73 |
| 9 | Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial | Blood | 2007 | 70 |
| 10 | Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study | Lancet Haematology,the | 2017 | 69 |
| 11 | Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study | Haematologica | 2017 | 68 |
| 12 | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study | Leukemia | 2018 | 67 |
| 13 | IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW | Mediterranean Journal of Hematology and Infectious Diseases | 2014 | 63 |
| 14 | Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL | Bone Marrow Transplantation | 2010 | 56 |
| 15 | Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma | Journal of the American Society of Hypertension | 2014 | 53 |
| 16 | Randomized transcoronary delivery of CD34+ cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of 99mTc-labeled cells activity | Journal of Nuclear Cardiology | 2011 | 51 |
| 17 | Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen — A national multicenter study | International Journal of Cardiology | 2013 | 41 |
| 18 | Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia | Leukemia | 2001 | 35 |
| 19 | Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma | Journal of Clinical Immunology | 2007 | 34 |
| 20 | The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective | Oncologist | 2016 | 28 |
| 21 | Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience | Annals of Hematology | 2004 | 27 |
| 22 | Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study | Annals of Hematology | 2019 | 25 |
| 23 | Outcomes of treatment with dose‐adjusted EPOCH‐R or R‐CHOP in primary mediastinal large B‐cell lymphoma | European Journal of Haematology | 2020 | 25 |
| 24 | Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients | Blood | 2016 | 24 |
| 25 | Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia | Leukemia and Lymphoma | 2009 | 23 |
| 26 | Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia | Molecular Medicine Reports | 2015 | 18 |
| 27 | Efficacy and Safety of Fludarabine and Cyclophosphamide Combined Therapy in Patients with Refractory/Recurrent B-Cell Chronic Lymphocytic Leukaemia (B-CLL)—Polish Multicentre Study | Leukemia and Lymphoma | 2004 | 17 |
| 28 | Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients | Leukemia Research | 2014 | 16 |
| 29 | Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review | Leukemia and Lymphoma | 2019 | 16 |
| 30 | Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology | Seminars in Oncology | 2019 | 16 |
| 31 | Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma | Frontiers in Oncology | 2020 | 16 |
| 32 | 2‐Chlorodeoxyadenosine (cladribine)‐related eosinophilia in patients with lymphoproliferative diseases | European Journal of Haematology | 1997 | 15 |
| 33 | Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus | Leukemia and Lymphoma | 2017 | 15 |
| 34 | Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group | Biology of Blood and Marrow Transplantation | 2020 | 14 |
| 35 | The Gain-of-Function JAK2 V617F Mutation Shifts the Phenotype of Essential Thrombocythemia and Chronic Idiopathic Myelofibrosis to More "Erythremic" and Less "Thrombocythemic": A Molecular, Histologic, and Clinical Study | International Journal of Hematology | 2007 | 13 |
| 36 | Avatrombopag for the treatment of immune thrombocytopenia | Expert Review of Clinical Immunology | 2019 | 12 |
| 37 | Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report | Scientific Reports | 2020 | 12 |
| 38 | Mantle Cell Lymphoma of Mucosa‐Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study | HemaSphere | 2020 | 10 |
| 39 | Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study | Blood | 2018 | 10 |
| 40 | Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia | Leukemia and Lymphoma | 1996 | 10 |
| 41 | Use of acalabrutinib in patients with mantle cell lymphoma | Expert Review of Hematology | 2018 | 9 |
| 42 | Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study | Clinical Lymphoma, Myeloma and Leukemia | 2019 | 9 |
| 43 | Acalabrutinib for adults with mantle cell lymphoma | Expert Review of Clinical Pharmacology | 2019 | 9 |
| 44 | Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves | Vascular Pharmacology | 2020 | 9 |
| 45 | Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study | Blood | 2016 | 9 |
| 46 | Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study. | Journal of Clinical Oncology | 2019 | 9 |
| 47 | Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report | Journal of Medical Case Reports | 2016 | 8 |
| 48 | Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders | International Journal of Cardiology | 2017 | 8 |
| 49 | Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study | Anticancer Research | 2020 | 8 |
| 50 | Six molecular patterns leading to hemophilia A phenotype in 18 females from Poland | Thrombosis Research | 2020 | 8 |
